Lake Street analyst Chad Messer raised the firm’s price target on Bolt Biotherapeutics (BOLT) to $75 from $4 and keeps a Buy rating on the shares after Bolt ended Q2 with $48.5M in cash and reiterated its cash runway through mid-2026. The company completed a 20:1 reverse stock split to regain compliance with Nasdaq listing requirements in June, notes the analyst, who adjusted the firm’s target to account for the reverse split.
TipRanks Cyber Monday Sale
- Claim 60% off TipRanks Premium for data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on BOLT: